logo
Share SHARE
FONT-SIZE Plus   Neg

Target To Continue Buybacks; Plans To Grow Annual Dividend To $3 By 2017

Target Corp. (TGT) said Monday that it has completed the $10 billion share repurchase program authorized by its board of directors in November 2007.

Under the program, the company repurchased 193.5 million shares, representing nearly 23% of its November 2007 outstanding shares, at an average price of $51.68 per share.

The company said it will continue to repurchase shares under the $5 billion program approved by its board of directors in January this year, which it expects to complete in the next 2 to 3 years.

John Mulligan, incoming EVP and chief financial officer of Target, said, "Through disciplined financial management, Target continues to generate far more cash than we need to fund appropriate reinvestment in our core businesses. As a result, we intend to continue to invest in the repurchase of shares under our January 2012 authorization."

The company also said that it expects to continue to grow the dividend at a robust pace which would allow the annual dividend to rise to $3.00 or more by 2017, assuming the company meets its goal to grow annual earnings per share to $8.00 or more by that time.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported a profit for the first-quarter of 2017 that declined 20 percent from the prior year. Net revenues declined 11%, reflecting unfavorable impacts from structural changes of 10% and foreign currency of 1%. The company remains on track to deliver its underlying revenue and profit targets for the full year. Eli Lilly and Co. (LLY) reported a loss for the first quarter of 2017 compared to profit in the prior year, primarily hurt by lower operating income, partially offset by higher other income. But, quarterly revenue increased 7 percent, driven by 9 percent pharmaceutical volume growth from Trulicity, Taltz and other new products. Capricor Therapeutics, Inc., a clinical-stage biotechnology company for cardiac and other medical conditions, announced Tuesday positive six-month results from the randomized phase I/II HOPE clinical trial in Duchenne muscular dystrophy or DMD. The HOPE clinical trial was designed to evaluate the safety and exploratory efficacy of CAP-1002.
comments powered by Disqus
Follow RTT